The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

Autor:	Fiona J. Dore, Cleyton C. Domingues, Neeki Ahmadi, Nabanita Kundu, Yana Kropotova, Sara Houston, Carol Rouphael, Aytan Mammadova, Linda Witkin, Anamil Khiyami, Richard L. Amdur, Sabyasachi Sen
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	Diabetes Endothelial progenitor cells Saxagliptin DPP-4 inhibitor Arterial stiffness Diseases of the circulatory (Cardiovascular) system RC666-701
Zdroj:	Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Druh dokumentu:	article
ISSN:	1475-2840
DOI:	10.1186/s12933-018-0709-9
Popis:	Abstract Aims Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be used as a cardiovascular disease risk biomarker. This study investigated whether the addition of saxagliptin, a DPP-IV inhibitor, to metformin, may reduce cardiovascular disease risk in addition to improving glycemic control in Type 2 diabetes patients. Methods In 12 week, double-blind, randomized placebo-controlled trial, 42 subjects already taking metformin 1–2 grams/day were randomized to placebo or saxagliptin 5 mg. Subjects aged 40–70 years with diabetes for
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/6b9c71fc3a5945c4a41c250bc4a60d3d Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.